Skip to main content

ICUI

Stock
Health Care
Medical Instruments & Supplies

Performance overview

ICUI Price
Price Chart

Forward-looking statistics

Beta
0.64
Risk
41.07%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees10K
Market cap$2.7B

Fundamentals

Enterprise value$4.6B
Revenue$2.4B
Revenue per employee
Profit margin-3.87%
Debt to equity80.57

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.83
Dividend per share
Revenue per share$98.91
Avg trading volume (30 day)$29M
Avg trading volume (10 day)$34M
Put-call ratio

Macro factor sensitivity

Growth-0.0
Credit+4.0
Liquidity-0.6
Inflation-2.4
Commodities-0.0
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio19.83
Price to sales1.38
P/E Ratio19.83
Enterprise Value to Revenue1.88
Price to book1.68

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates

ICU Medical (ICUI) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.96 per share a year ago.

Zacks Investment Research (May 8, 2025)
Raymond James Says 'Supply Chain Challenges Made Q1 Messy' For This Medtech Stock

ICU Medical Inc (NASDAQ: ICUI) reported Q1 sales of $543.1 million vs. Raymond James' estimate of $530 million.

Benzinga (May 11, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free